Cargando…

Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties

BACKGROUND: Addiction, overdoses and deaths resulting from prescription opioids have increased dramatically over the last decade. In response, several manufacturers have developed formulations of opioids with abuse-deterrent properties. For many of these products, the Food and Drug Administration (F...

Descripción completa

Detalles Bibliográficos
Autores principales: Janoff, Shannon L., Perrin, Nancy A., Coplan, Paul M., Chilcoat, Howard D., Campbell, Cynthia I., Green, Carla A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867981/
https://www.ncbi.nlm.nih.gov/pubmed/27177423
http://dx.doi.org/10.1186/s40360-016-0064-y
_version_ 1782432118528278528
author Janoff, Shannon L.
Perrin, Nancy A.
Coplan, Paul M.
Chilcoat, Howard D.
Campbell, Cynthia I.
Green, Carla A.
author_facet Janoff, Shannon L.
Perrin, Nancy A.
Coplan, Paul M.
Chilcoat, Howard D.
Campbell, Cynthia I.
Green, Carla A.
author_sort Janoff, Shannon L.
collection PubMed
description BACKGROUND: Addiction, overdoses and deaths resulting from prescription opioids have increased dramatically over the last decade. In response, several manufacturers have developed formulations of opioids with abuse-deterrent properties. For many of these products, the Food and Drug Administration (FDA) recognized the formulation with labeling claims and mandated post-marketing studies to assess the abuse-deterrent effects. In response, we assess differences in rates of opioid-related overdoses and poisonings prior to and following the introduction of a formulation of OxyContin® with abuse-deterrent properties. METHODS/DESIGN: To assess effects of this formulation, electronic medical record (EMR) data from Kaiser Permanente Northwest (KPNW) and Kaiser Permanente Northern California (KPNC) are linked to state death data and compared to chart audits. Overdose and poisoning events will be categorized by intentionality and number of agents involved, including illicit drugs and alcohol. Using 6-month intervals over a 10-year period, trends will be compared in rates of opioid-related overdoses and poisoning events associated with OxyContin® to rates of events associated with other oxycodone and opioid formulations. Qualitative interviews with patients and relatives of deceased patients will be conducted to capture circumstances surrounding events. DISCUSSION: This study assesses and tracks changes in opioid-related overdoses and poisoning events prior to and following the introduction of OxyContin® with abuse-deterrent properties. Public health significance is high because these medications are designed to reduce abuse-related behaviors that lead to important adverse outcomes, including overdoses and deaths. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-016-0064-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4867981
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48679812016-05-17 Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties Janoff, Shannon L. Perrin, Nancy A. Coplan, Paul M. Chilcoat, Howard D. Campbell, Cynthia I. Green, Carla A. BMC Pharmacol Toxicol Study Protocol BACKGROUND: Addiction, overdoses and deaths resulting from prescription opioids have increased dramatically over the last decade. In response, several manufacturers have developed formulations of opioids with abuse-deterrent properties. For many of these products, the Food and Drug Administration (FDA) recognized the formulation with labeling claims and mandated post-marketing studies to assess the abuse-deterrent effects. In response, we assess differences in rates of opioid-related overdoses and poisonings prior to and following the introduction of a formulation of OxyContin® with abuse-deterrent properties. METHODS/DESIGN: To assess effects of this formulation, electronic medical record (EMR) data from Kaiser Permanente Northwest (KPNW) and Kaiser Permanente Northern California (KPNC) are linked to state death data and compared to chart audits. Overdose and poisoning events will be categorized by intentionality and number of agents involved, including illicit drugs and alcohol. Using 6-month intervals over a 10-year period, trends will be compared in rates of opioid-related overdoses and poisoning events associated with OxyContin® to rates of events associated with other oxycodone and opioid formulations. Qualitative interviews with patients and relatives of deceased patients will be conducted to capture circumstances surrounding events. DISCUSSION: This study assesses and tracks changes in opioid-related overdoses and poisoning events prior to and following the introduction of OxyContin® with abuse-deterrent properties. Public health significance is high because these medications are designed to reduce abuse-related behaviors that lead to important adverse outcomes, including overdoses and deaths. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-016-0064-y) contains supplementary material, which is available to authorized users. BioMed Central 2016-05-14 /pmc/articles/PMC4867981/ /pubmed/27177423 http://dx.doi.org/10.1186/s40360-016-0064-y Text en © Janoff et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Janoff, Shannon L.
Perrin, Nancy A.
Coplan, Paul M.
Chilcoat, Howard D.
Campbell, Cynthia I.
Green, Carla A.
Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties
title Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties
title_full Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties
title_fullStr Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties
title_full_unstemmed Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties
title_short Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties
title_sort protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of oxycontin® with abuse-deterrent properties
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867981/
https://www.ncbi.nlm.nih.gov/pubmed/27177423
http://dx.doi.org/10.1186/s40360-016-0064-y
work_keys_str_mv AT janoffshannonl protocolchangesinratesofopioidoverdoseandpoisoningeventsinanintegratedhealthsystemfollowingtheintroductionofaformulationofoxycontinwithabusedeterrentproperties
AT perrinnancya protocolchangesinratesofopioidoverdoseandpoisoningeventsinanintegratedhealthsystemfollowingtheintroductionofaformulationofoxycontinwithabusedeterrentproperties
AT coplanpaulm protocolchangesinratesofopioidoverdoseandpoisoningeventsinanintegratedhealthsystemfollowingtheintroductionofaformulationofoxycontinwithabusedeterrentproperties
AT chilcoathowardd protocolchangesinratesofopioidoverdoseandpoisoningeventsinanintegratedhealthsystemfollowingtheintroductionofaformulationofoxycontinwithabusedeterrentproperties
AT campbellcynthiai protocolchangesinratesofopioidoverdoseandpoisoningeventsinanintegratedhealthsystemfollowingtheintroductionofaformulationofoxycontinwithabusedeterrentproperties
AT greencarlaa protocolchangesinratesofopioidoverdoseandpoisoningeventsinanintegratedhealthsystemfollowingtheintroductionofaformulationofoxycontinwithabusedeterrentproperties